San Francisco, CA April 10, 2012 Medizone International, Inc. (MZEI:OB) (MZEI:QB) announced today that the first production unit of its AsepticSure disinfection technology has been successfully completed by its manufacturing partner, SMTC Corporation (NASDAQ:SMTX).
Following performance confirmation testing of the initial unit, four additional units will immediately be manufactured for independent validation testing and subsequently placed into commercial service. The first five production units are expected to be delivered to Medizone by month’s end.
“Our peer reviewed article in the AJIC and more recent recognition in Geneva for Innovation Excellence marked the beginning of a series of amazing achievements for Medizone,” stated Dr Michael Shannon, President and Director of Medical Affairs.
“A combination of scientific, developmental and technological advancements made by the Company over the past 12 months has seen us arrive at the brink of an exciting new era in Medizone’s history.
“I have no doubt whatsoever that AsepticSure is poised to become the gold standard for hospital disinfection,” said Shannon.”
Medizone International’s Chairman and CEO, Edwin Marshall commented: “In addition to successfully initiating production, we’re pleased to announce that Health Canada recently informed us that they will not regulate AsepticSure as either a medical device or disinfectant. Additionally, they will not require a new DIN (drug identification number) for the AsepticSure catalyst.
“The Company views this ruling by Health Canada in the most favorable light. It means that following standard validation testing of the initial production units over the coming 4 weeks, the Company may then begin commercial sales of AsepticSure in Canada.
“For Medizone to successfully develop and launch such a superior, fast-acting (green) disinfection technology capable of consistently producing 100% bacterial kills on both hard and soft surfaces without leaving any residual residue… it’s an amazing achievement. Our R&D, science, regulatory, patent and production teams have done an outstanding job. I couldn’t be more proud of them.”
In related news, Medizone’s regulatory team has also submitted a Request for Designation in the US, to the FDA.
For press information on Medizone International, please contact:
Bruce Smeaton, Investor Relations, Medizone International, Inc.
T: 001-415-331-0202 E: firstname.lastname@example.org
Medizone International, Inc. is engaged in initial production of its modular design AsepticSure™ Decontamination Systems. Decontamination to the sterilization standard of >6 log (99.9999%) is obtainable within hospitals, airlines, cruise ships, long term care facilities, food processing plants, clean room manufacturing facilities, schools and other critical infrastructure. A government variant is being tested for bio-terrorism counter measures for building remediation.
This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.
For more information, visit: www.medizoneint.com